JP2019112445A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112445A5
JP2019112445A5 JP2019047201A JP2019047201A JP2019112445A5 JP 2019112445 A5 JP2019112445 A5 JP 2019112445A5 JP 2019047201 A JP2019047201 A JP 2019047201A JP 2019047201 A JP2019047201 A JP 2019047201A JP 2019112445 A5 JP2019112445 A5 JP 2019112445A5
Authority
JP
Japan
Prior art keywords
peptide
fusion polypeptide
val
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019047201A
Other languages
English (en)
Japanese (ja)
Other versions
JP7096186B2 (ja
JP2019112445A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112445A publication Critical patent/JP2019112445A/ja
Publication of JP2019112445A5 publication Critical patent/JP2019112445A5/ja
Application granted granted Critical
Publication of JP7096186B2 publication Critical patent/JP7096186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019047201A 2012-07-31 2019-03-14 免疫応答の調節 Active JP7096186B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677596P 2012-07-31 2012-07-31
US61/677,596 2012-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015525500A Division JP2015525781A (ja) 2012-07-31 2013-07-30 免疫応答の調節

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020161836A Division JP2020200351A (ja) 2012-07-31 2020-09-28 免疫応答の調節

Publications (3)

Publication Number Publication Date
JP2019112445A JP2019112445A (ja) 2019-07-11
JP2019112445A5 true JP2019112445A5 (enExample) 2019-11-28
JP7096186B2 JP7096186B2 (ja) 2022-07-05

Family

ID=50028463

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015525500A Pending JP2015525781A (ja) 2012-07-31 2013-07-30 免疫応答の調節
JP2019047201A Active JP7096186B2 (ja) 2012-07-31 2019-03-14 免疫応答の調節
JP2020161836A Pending JP2020200351A (ja) 2012-07-31 2020-09-28 免疫応答の調節

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015525500A Pending JP2015525781A (ja) 2012-07-31 2013-07-30 免疫応答の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020161836A Pending JP2020200351A (ja) 2012-07-31 2020-09-28 免疫応答の調節

Country Status (5)

Country Link
US (2) US10513540B2 (enExample)
EP (2) EP2879709B1 (enExample)
JP (3) JP2015525781A (enExample)
CA (1) CA2916638C (enExample)
WO (1) WO2014022332A1 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10081679B2 (en) 2013-11-25 2018-09-25 Ccam Biotherapeutics Ltd. Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP4406610A3 (en) 2014-04-07 2024-10-30 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
MX390943B (es) 2014-07-21 2025-03-21 Novartis Ag Receptores de antígeno quimérico cd33 y usos de los mismos.
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
JP6709215B2 (ja) 2014-10-27 2020-06-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗ｔｉｍ−３抗体
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016171722A1 (en) * 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
EP3344996A2 (en) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
RS63125B1 (sr) 2015-11-03 2022-05-31 Janssen Biotech Inc Antitela koja se specifično vezuju za pd-1 i njihova upotreba
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN109069623A (zh) 2015-12-18 2018-12-21 诺华股份有限公司 靶向CD32b的抗体及其使用方法
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
JP2019513347A (ja) 2016-03-04 2019-05-30 ノバルティス アーゲー 複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
US10639368B2 (en) 2016-05-27 2020-05-05 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Anti-pd-l1 antibodies
TW202244061A (zh) 2016-07-14 2022-11-16 美商必治妥美雅史谷比公司 針對tim3之抗體及其用途
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
IL272697B2 (en) 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
MY208825A (en) 2018-06-13 2025-05-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
JP7742773B2 (ja) 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
SG11202105084VA (en) 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
ES2981569T3 (es) 2018-11-30 2024-10-09 Juno Therapeutics Inc Métodos de tratamiento usando terapia celular adoptiva
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3946619A1 (en) 2019-03-26 2022-02-09 The Regents Of The University Of Michigan Small molecule degraders of stat3
US20220185831A1 (en) 2019-03-29 2022-06-16 The Regents Of The University Of Michigan Stat3 protein degraders
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US20220304984A1 (en) 2019-06-12 2022-09-29 Vanderbilt University Amino acid transport inhibitors and the uses thereof
WO2020252336A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
BR112021026334A2 (pt) 2019-06-27 2022-05-10 Medstar Health Macrófagos ativados por hdac6, composições, e usos dos mesmos
CA3138560A1 (en) 2019-07-16 2021-01-21 Shaomeng Wang Imidazopyrimidines as eed inhibitors and the use thereof
CA3151824A1 (en) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
WO2021055756A1 (en) 2019-09-19 2021-03-25 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
WO2021059075A1 (en) * 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
PH12022551290A1 (en) 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
CN111533785B (zh) * 2020-02-11 2022-03-08 北京市肿瘤防治研究所 靶向免疫检查点tim3结合肽及其应用
WO2021195481A1 (en) 2020-03-26 2021-09-30 The Regents Of The University Of Michigan Small molecule stat protein degraders
EP4132542A2 (en) 2020-04-10 2023-02-15 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4153597B1 (en) 2020-05-19 2025-09-10 Pharmacosmos Holding A/S Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
WO2024165403A1 (en) 2023-02-06 2024-08-15 Philogen S.P.A. Anti-cea antibodies
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DE69925909T2 (de) 1998-04-15 2006-05-11 Brigham & Women's Hospital, Inc., Boston T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
SE0002835D0 (sv) * 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
EP1467759A4 (en) 2002-01-30 2006-05-31 Brigham & Womens Hospital COMPOSITIONS AND METHODS ASSOCIATED WITH TIM-3, TH1-SPECIFIC CELL SURFACE MOLECULE
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
WO2005023870A1 (ja) 2003-09-04 2005-03-17 Riken ＴＧＦ－β活性化制御領域の切断面を認識する抗体
WO2005033144A2 (en) 2003-10-03 2005-04-14 Brigham And Women's Hospital Tim-3 polypeptides
WO2005058358A2 (en) 2003-12-17 2005-06-30 Nalan Utku Use of agents derived from ceacam1 for the treatment of inflammatory diseases
US8815248B2 (en) 2005-06-09 2014-08-26 Gal Markel Modulation of immunity and CEACAM1 activity
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
US9416165B2 (en) * 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
US8647623B2 (en) * 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
ES2668874T3 (es) * 2009-04-30 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
PT2581113T (pt) * 2010-06-11 2018-07-04 Univ Kyushu Nat Univ Corp Anticorpo anti-tim-3
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
DE102010024636B4 (de) * 2010-06-22 2024-04-18 Universität Duisburg-Essen Antikörper, insbesondere für die Diagnostik
JP6385277B2 (ja) 2011-12-01 2018-09-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌治療のための抗ｃｅａｃａｍ１組換え型抗体

Similar Documents

Publication Publication Date Title
JP2019112445A5 (enExample)
Niesner et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides
JP5994068B2 (ja) ＩｇＧ結合性ペプチド及びそれによるＩｇＧの検出および精製方法
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
JP2019528077A5 (enExample)
US20210284716A1 (en) ACE2-Fc Trap
JP2019519227A5 (enExample)
JP2016519932A5 (enExample)
JP2010539921A5 (enExample)
US20180194819A1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation
JP2015509097A5 (enExample)
CA2863944A1 (en) Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
MX2007003320A (es) Moleculas fc modificadas.
CN108463469B (zh) 一种与抗可替宁抗体连接的嵌合抗原受体及其用途
JP6738340B2 (ja) 新規なｅｇｆｒ結合タンパク質
JP2018532372A5 (enExample)
Oudin et al. A soluble recombinant multimeric anti-Rh (D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes
JP2018535972A5 (enExample)
JP2017529870A5 (enExample)
JP2008521426A5 (enExample)
Kim et al. Tribody: robust self-assembled trimeric targeting ligands with high stability and significantly improved target-binding strength
WO1995011975A3 (en) Retroviral superantigens, superantigen peptides, and methods of use
HRP20161449T1 (hr) Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena
JP2021506310A5 (enExample)
Vostakolaei et al. Isolation and characterization of a novel scFv antibody fragments specific for Hsp70 as a tumor biomarker